What is the Market's View on Adaptive Biotechnologies Corp (ADPT) Stock's Price and Volume Trends Wednesday?

Adaptive Biotechnologies Corp (ADPT) stock is higher by 3.50% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Adaptive Biotechnologies Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ADPT!

See Full ADPT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ADPT Stock Today?

Adaptive Biotechnologies Corp (ADPT) stock is trading at $6.80 as of 12:35 PM on Wednesday, Sep 13, a gain of $0.13, or 1.87% from the previous closing price of $6.67. The stock has traded between $6.65 and $6.86 so far today. Volume today is low. So far 351,090 shares have traded compared to average volume of 1,267,500 shares. To see InvestorsObserver's Sentiment Score for Adaptive Biotechnologies Corp click here.

More About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Click Here to get the full Stock Report for Adaptive Biotechnologies Corp stock.